Navigation Links
BioCryst's Partner Shionogi Receives Marketing & Manufacturing Approval For Peramivir in Japan
Date:1/13/2010

BIRMINGHAM, Ala., Jan. 13 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its partner, Shionogi & Co., Ltd. has received marketing and manufacturing approval for intravenous (i.v.) peramivir to treat patients with influenza in Japan.  Shionogi intends to commercially launch peramivir under the commercial name RAPIACTA in Japan, pending the product's National Health Insurance (NHI) price listing.

As a result of this approval, BioCryst will receive a third and final regulatory milestone payment of $7 million under its license agreement with Shionogi.  BioCryst may receive future commercial event milestone payments of up to $95 million from Shionogi.

"This first approval of a BioCryst discovered drug is a major step in our journey towards building an enduring and successful biopharmaceutical company," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst.  "We congratulate Shionogi on receiving rapid approval of peramivir, one of the quickest marketing authorizations ever granted by the Japanese authorities.  BioCryst continues to work with other governments and our partners to make i.v. peramivir available as a treatment option for hospitalized patients with influenza during the ongoing pandemic, and to complete the development of peramivir as a seasonal influenza treatment in the future."

Shionogi received the indications of single dose administration of 300 mg i.v. peramivir for adult uncomplicated seasonal influenza infection, as well as single and multiple dose administration of 600 mg i.v. peramivir for the patient
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Microbix And Therapure Biopharma Form Partnership To Expand Water-Based Supplies To The Pharma Industry
2. TechCFO Continues Research Triangle Park Expansion; Garrison Named New Partner
3. Waukesha Electric partners with SuperPower and UH to build fault current limiting superconducting transformer for Dept. of Energy
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. Array BioPharma and Amgen Partner in Type 2 Diabetes
6. Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner
7. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
8. Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators
9. Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies
10. Mercy Ships and MediSend International Partner to Deliver Hope and Healing
11. DNA Genotek Launches Global Partner Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine ... achieved 50% enrollment of the total projected enrollment ... the safety and preliminary efficacy of the medical ... for Knee Osteoarthritis (KOA). To date the trial ... The Phase I open label clinical ...
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce ... Switzerland -based Kenta Biotech to acquire ... (mAb) products, and technologies. This asset portfolio purchase ... of infections by common pathogens including drug resistant ... Pseudomonas aeruginosa , Acinetobacter baumannii and ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Men’s skin is ... La-roche Posay ) and has been known to react ... some men may be far from puberty, other acne causing ... pores, causing breakouts, and threatening skin with unsightly acne scars. ... from Men’s Health on how to reduce and ...
(Date:5/17/2013)... May 17, 2013 RURO Inc. ... version 4.1, a versatile refinement to the smart ... solution, improves its advanced methodical management for transgenic ... ezColony 4.1. The network-based platform provides user access ... research. While continuing to emphasize streamlined tasks, such ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... - PAS-Port(R) Proximal Anastomosis System Received 510(k) Clearance from ... Food and Drug Administration (FDA) -, - Development Progress Triggered $1M Milestone ... - Conference Call Today at 4:30 p.m. Eastern Time -, ... today reported financial results and corporate progress,for its fiscal 2009 first quarter ...
... Beckman,Coulter, Inc. (NYSE: BEC ), announced today ... Adventist Health to provide a broad range of ... million over,six years. Adventist Health is a not-for-profit, ... Oregon, and Washington., (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ), ...
... ... Clinical Business, SUNNYVALE, Calif., Oct. 28 Cepheid (Nasdaq:,CPHD) today ... of 24% over the third quarter of fiscal 2007. Net loss,was $6.5 ... a net loss of $4.7 million, or $(0.09) per share, in the ...
Cached Biology Technology:Cardica Announces Fiscal 2009 First Quarter Financial Results 2Cardica Announces Fiscal 2009 First Quarter Financial Results 3Cardica Announces Fiscal 2009 First Quarter Financial Results 4Cardica Announces Fiscal 2009 First Quarter Financial Results 5Cardica Announces Fiscal 2009 First Quarter Financial Results 6Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care 2Cepheid Reports Third Quarter Revenue of $44.9 Million 2Cepheid Reports Third Quarter Revenue of $44.9 Million 3Cepheid Reports Third Quarter Revenue of $44.9 Million 4Cepheid Reports Third Quarter Revenue of $44.9 Million 5Cepheid Reports Third Quarter Revenue of $44.9 Million 6Cepheid Reports Third Quarter Revenue of $44.9 Million 7Cepheid Reports Third Quarter Revenue of $44.9 Million 8Cepheid Reports Third Quarter Revenue of $44.9 Million 9Cepheid Reports Third Quarter Revenue of $44.9 Million 10Cepheid Reports Third Quarter Revenue of $44.9 Million 11Cepheid Reports Third Quarter Revenue of $44.9 Million 12Cepheid Reports Third Quarter Revenue of $44.9 Million 13
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... new Dartmouth College study finds human-caused climate change ... tropical lizards, contradicting a host of recent studies ... warming planet. , The findings, which appear in ... new hope for survival of a creature thought ... predictions that tropical cold-blooded animals, especially forest lizards, ...
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... (ENDO) 95th Annual Meeting in San Francisco, CA ... to promote the entry of students, postdoctorates and ... the basic science community and to encourage the ... Annual Meeting. , Awards are given to poster/platform ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2Climate change may have little impact on tropical lizards 2
... have long been puzzled by a condition called ... of the brain become elongated and misshapen. Typically, ... ("hardening of the arteries"), and not directly life-threatening. ... dolichoectasia are more likely to have aortic aneurysms, ...
... species (ROS), or 'oxygen radicals', have been identified as ... prevalence linked to inflammation-associated syndromes and a variety of ... San Diego Branch of the Ludwig Institute for Cancer ... repair and cell cycle control genes in yeast that ...
... time when everything was big has helped Queensland researchers ... humans, was responsible for wiping out Australian giant marsupials ... excavating 'trophy specimens' such as giant kangaroos and wombats, ... Queensland Museum performed the first systematic analysis of a ...
Cached Biology News:Mystery Blood Vessel Disorder Implicated In 'Mini' Strokes 2Yeast Network Prevents Damage By Oxygen Radicals 2Small species back-up giant marsupial climate change extinction claim 2Small species back-up giant marsupial climate change extinction claim 3
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
... an anodized aluminum, solvent-resistant block specially designed ... efficient thermal transfer to samples within the ... HT96 Isothermal Block replaces Cat. No. 71031-3, ... for compatibility with robotic applications. The new ...
Biology Products: